Founder, CEO
Dr. Alderete has successfully applied his wide range of experience and formal training to the evaluation, financing, formation and operation of several med-tech companies.
John has deep life sciences experience that includes basic and translational research, program management (both scientific and product level), product development, strategic and business development, technology assessment and development, fundraising and clinical trial design, implementation and data assessment. He has experience with medical devices, diagnostics, vaccines and therapeutics, with an emphasis in infectious diseases and oncology.
John is the Founder and President of Folium BioMed LLC, an investment and product development company. He is the currently the CEO and founder of Biomirror Diagnostics, focused on disease reporting for the next pandemic event.
Prior to Biomirror, John served as managing partner of Apollos Diagnostics™ LLC, where he led the team to develop the world’s first antibody collection specific to SARS-CoV-2 encompassing antibodies directed against all viral proteins. As well, John’s team developed the EXPRESSC2™ Rapid COVID19 Antigen Test against SARS-CoV-2. This rapid test in lateral flow assay form was demonstrated to be one of the best performing rapid tests on the market and was successfully submitted to the US FDA under the Emergency Use Authorization act.
John was a senior consultant and project manager for a product-level pharmaceutical and biotechnology consulting firm in Palo Alto, focusing on strategic planning decision in complex diseases, new markets and new technologies.
While a part of Stanford University’s School of Medicine Corporate and Foundation Relations team, John was instrumental in helping to define the corporate engagement landscape for the School of Medicine.
Industry Focus
In addition to being a CEO of Biomirror, John also advises and coaches companies and med-tech CEOs on product development, business strategy, corporate governance, and executive leadership.